| Literature DB >> 34480806 |
S Pradhan, R A Schwartz1, A Patil2, S Grabbe3,4, M Goldust4.
Abstract
Leishmaniasis is broadly classified into three types: cutaneous, mucocutaneous and visceral. The visceral form is most dangerous and can result in death. Although leishmaniasis is an ancient disease, its treatment is still challenging. Several drugs, differing in their cost, toxicity, treatment duration and emergence of drug resistance, are used for different types of leishmaniasis. To overcome these limitations, the search for newer drugs and other treatments continues. In this article, we discuss conventional drugs, other treatments, including newer options such as immunotherapy and immunochemotherapy, and future prospects for leishmaniasis treatment.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34480806 DOI: 10.1111/ced.14919
Source DB: PubMed Journal: Clin Exp Dermatol ISSN: 0307-6938 Impact factor: 3.470